FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035131797> ?p ?o ?g. }

• W2035131797 endingPage "204" @default.
• W2035131797 startingPage "200" @default.
• W2035131797 abstract "Objectives To assess the efficacy of enuresis alarm (EA) treatment in pharmacotherapy-resistant nocturnal enuresis (PRNE). Material and Methods A retrospective study was performed in children who received EA treatment as a form of combination treatment for PRNE from June 1999 to December 2007. The children included 54 monosymptomatic nocturnal enuresis (MNE) children who had partial response or nonresponse to desmopressin (group 1), 25 nonmonosymptomatic nocturnal enuresis (NMNE) children who had partial response or nonresponse to extended release oxybutynin plus desmopressin (group 2), and 21 MNE or NMNE children who relapsed after responding fully to first-line pharmacotherapy (group 3). EA treatment outcomes were determined as outlined by the International Children's Continence Society Standardisation Committee. Results Overall, 50% and 53.7%, 40%, and 52.4% of children in groups 1, 2, and 3, respectively, responded fully to EA treatment (no significant differences). In groups 1 and 2, 54.4% (31/57) of the partial responders and 36.4% (8/22) of the nonresponders showed full response (FR) after EA treatment was initiated. Of the children with small bladder capacities, 56.7% showed FR. Of the full responders in each group, 60.7%, 88.9%, and 54.5% of groups 1, 2, and 3, respectively, did not have relapse 6 months after cessation of treatment. Conclusions Overall, half of the total population achieved FR, and continued success was observed in more than half of full responders irrespective of the groups. Thus, adding EA treatment to pharmacotherapy is an effective second-line therapeutic strategy for children with PRNE. To assess the efficacy of enuresis alarm (EA) treatment in pharmacotherapy-resistant nocturnal enuresis (PRNE). A retrospective study was performed in children who received EA treatment as a form of combination treatment for PRNE from June 1999 to December 2007. The children included 54 monosymptomatic nocturnal enuresis (MNE) children who had partial response or nonresponse to desmopressin (group 1), 25 nonmonosymptomatic nocturnal enuresis (NMNE) children who had partial response or nonresponse to extended release oxybutynin plus desmopressin (group 2), and 21 MNE or NMNE children who relapsed after responding fully to first-line pharmacotherapy (group 3). EA treatment outcomes were determined as outlined by the International Children's Continence Society Standardisation Committee. Overall, 50% and 53.7%, 40%, and 52.4% of children in groups 1, 2, and 3, respectively, responded fully to EA treatment (no significant differences). In groups 1 and 2, 54.4% (31/57) of the partial responders and 36.4% (8/22) of the nonresponders showed full response (FR) after EA treatment was initiated. Of the children with small bladder capacities, 56.7% showed FR. Of the full responders in each group, 60.7%, 88.9%, and 54.5% of groups 1, 2, and 3, respectively, did not have relapse 6 months after cessation of treatment. Overall, half of the total population achieved FR, and continued success was observed in more than half of full responders irrespective of the groups. Thus, adding EA treatment to pharmacotherapy is an effective second-line therapeutic strategy for children with PRNE." @default.
• W2035131797 created "2016-06-24" @default.
• W2035131797 creator A5008000395 @default.
• W2035131797 creator A5034534478 @default.
• W2035131797 creator A5078246462 @default.
• W2035131797 date "2011-01-01" @default.
• W2035131797 modified "2023-10-17" @default.
• W2035131797 title "The Efficacy of Enuresis Alarm Treatment in Pharmacotherapy-Resistant Nocturnal Enuresis" @default.
• W2035131797 cites W1526546378 @default.
• W2035131797 cites W1604363595 @default.
• W2035131797 cites W1964125849 @default.
• W2035131797 cites W1983819236 @default.
• W2035131797 cites W2000615939 @default.
• W2035131797 cites W2002126870 @default.
• W2035131797 cites W2056024718 @default.
• W2035131797 cites W2060206634 @default.
• W2035131797 cites W2072800652 @default.
• W2035131797 cites W2079066685 @default.
• W2035131797 cites W2083875976 @default.
• W2035131797 cites W2087524918 @default.
• W2035131797 cites W2091136994 @default.
• W2035131797 cites W2099217668 @default.
• W2035131797 cites W2118785260 @default.
• W2035131797 cites W2125026895 @default.
• W2035131797 cites W2134811554 @default.
• W2035131797 cites W2159895793 @default.
• W2035131797 cites W2169049021 @default.
• W2035131797 cites W3196797181 @default.
• W2035131797 doi "https://doi.org/10.1016/j.urology.2010.06.050" @default.
• W2035131797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20947143" @default.
• W2035131797 hasPublicationYear "2011" @default.
• W2035131797 type Work @default.
• W2035131797 sameAs 2035131797 @default.
• W2035131797 citedByCount "11" @default.
• W2035131797 countsByYear W20351317972013 @default.
• W2035131797 countsByYear W20351317972014 @default.
• W2035131797 countsByYear W20351317972015 @default.
• W2035131797 countsByYear W20351317972017 @default.
• W2035131797 countsByYear W20351317972018 @default.
• W2035131797 countsByYear W20351317972022 @default.
• W2035131797 crossrefType "journal-article" @default.
• W2035131797 hasAuthorship W2035131797A5008000395 @default.
• W2035131797 hasAuthorship W2035131797A5034534478 @default.
• W2035131797 hasAuthorship W2035131797A5078246462 @default.
• W2035131797 hasConcept C126322002 @default.
• W2035131797 hasConcept C142724271 @default.
• W2035131797 hasConcept C167135981 @default.
• W2035131797 hasConcept C187212893 @default.
• W2035131797 hasConcept C204787440 @default.
• W2035131797 hasConcept C2777334680 @default.
• W2035131797 hasConcept C2777844464 @default.
• W2035131797 hasConcept C2778702241 @default.
• W2035131797 hasConcept C2778941218 @default.
• W2035131797 hasConcept C2780610425 @default.
• W2035131797 hasConcept C42219234 @default.
• W2035131797 hasConcept C500440147 @default.
• W2035131797 hasConcept C71924100 @default.
• W2035131797 hasConceptScore W2035131797C126322002 @default.
• W2035131797 hasConceptScore W2035131797C142724271 @default.
• W2035131797 hasConceptScore W2035131797C167135981 @default.
• W2035131797 hasConceptScore W2035131797C187212893 @default.
• W2035131797 hasConceptScore W2035131797C204787440 @default.
• W2035131797 hasConceptScore W2035131797C2777334680 @default.
• W2035131797 hasConceptScore W2035131797C2777844464 @default.
• W2035131797 hasConceptScore W2035131797C2778702241 @default.
• W2035131797 hasConceptScore W2035131797C2778941218 @default.
• W2035131797 hasConceptScore W2035131797C2780610425 @default.
• W2035131797 hasConceptScore W2035131797C42219234 @default.
• W2035131797 hasConceptScore W2035131797C500440147 @default.
• W2035131797 hasConceptScore W2035131797C71924100 @default.
• W2035131797 hasIssue "1" @default.
• W2035131797 hasLocation W20351317971 @default.
• W2035131797 hasLocation W20351317972 @default.
• W2035131797 hasOpenAccess W2035131797 @default.
• W2035131797 hasPrimaryLocation W20351317971 @default.
• W2035131797 hasRelatedWork W1546557604 @default.
• W2035131797 hasRelatedWork W2035131797 @default.
• W2035131797 hasRelatedWork W2100056512 @default.
• W2035131797 hasRelatedWork W2146137743 @default.
• W2035131797 hasRelatedWork W2341322279 @default.
• W2035131797 hasRelatedWork W2395443871 @default.
• W2035131797 hasRelatedWork W2406658493 @default.
• W2035131797 hasRelatedWork W2561011840 @default.
• W2035131797 hasRelatedWork W2740689350 @default.
• W2035131797 hasRelatedWork W2750168987 @default.
• W2035131797 hasVolume "77" @default.
• W2035131797 isParatext "false" @default.
• W2035131797 isRetracted "false" @default.
• W2035131797 magId "2035131797" @default.
• W2035131797 workType "article" @default.